BridgeBio And Burjeel Announce 'NADER' R&D Project
Portfolio Pulse from Benzinga Newsdesk
BridgeBio Pharma, Inc. and VPS Healthcare's Burjeel Holdings have announced a preliminary, non-binding Collaboration Agreement for project 'NADER'. The project aims to revolutionize early diagnosis and treatment of rare diseases in the UAE and the region. The partnership will conduct clinical trials and research in Abu Dhabi.
July 12, 2023 | 8:35 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BridgeBio Pharma's collaboration with Burjeel Holdings for project 'NADER' could potentially enhance its product portfolio and market reach in the MENA region.
The collaboration with Burjeel Holdings allows BridgeBio Pharma to leverage the advanced infrastructure of Abu Dhabi for clinical trials and research. This could potentially lead to the development of new treatments for rare diseases, enhancing BridgeBio's product portfolio and expanding its market reach in the MENA region.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100